Radnet, Inc. annual report, FY2014

Business context and reporting period

RadNet, Inc.’s Form 10-K covers the fiscal year ended December 31, 2014; it is an annual filing, not a standalone fourth-quarter report. RadNet operates outpatient diagnostic imaging centers and related PACS software and teleradiology businesses. At year-end it operated 259 centers in seven states and performed 4.83 million imaging procedures.

Financial performance and liquidity

The quarterly results table reports fourth-quarter 2014 revenue of approximately $185.6 million and net income attributable to RadNet common stockholders of $4.2 million, compared with $178.3 million and $1.2 million, respectively, in fourth-quarter 2013. The quarterly revenue row is labeled “net service fee revenue,” although its quarterly amounts sum to annual total net revenue; investors should verify the presentation against the filed statements.

At December 31, 2014, cash was $0.3 million, accounts receivable were $148.2 million, working capital was $58.7 million, and total equity was $7.7 million. Total debt obligations were $597.6 million, including $399.8 million of first-lien term loans, $180.0 million of second-lien term loans, and $15.3 million drawn on a $101.25 million revolving facility; reported remaining revolver availability was approximately $85 million. Cash used in investing activities was $53.6 million, including $41.7 million of property and equipment purchases. The company reported compliance with its debt covenants and said operating cash flow and available credit were expected to meet liquidity needs.

Material changes versus prior year

• Revenue rose 2.1% and procedure volume rose about 6.7%. However, same-center service-fee revenue declined 1.6%, attributed primarily to slightly lower procedure volume and lower Medicare reimbursement; acquisitions contributed growth.
• Capitation revenue increased 17.8% to $77.2 million, or 10.3% of total net revenue. The company also reported approximately 10.7% of revenue from capitation in its risk-factor discussion.
• Operating income increased to $53.3 million, while attributable net income fell to $1.4 million. Results included a $15.9 million loss on early extinguishment of senior notes and a $2.0 million meaningful-use incentive. The 2014 refinancing retired $200 million of 10⅜% notes and management estimated approximately $5.1 million in annual interest savings, but increased scheduled first-lien amortization.
• Operating cash flow declined by $5.4 million, with a substantial increase in accounts receivable noted in the cash-flow statement. Year-end cash fell from $8.4 million to $0.3 million.
• RadNet added a net nine centers during 2014, mainly through acquisitions in California and New York.

Outlook, risks and unusual items

Management described plans to grow existing facilities, pursue selective acquisitions, expand related businesses, improve equipment utilization, and control costs. It cited an aging population and wider adoption of imaging as potential industry growth drivers. The filing provides no specific quantified earnings or revenue guidance. Management noted seasonal weakness in the first quarter from winter weather and annual resets of patient deductibles.

Key risks include high leverage and debt-service demands, variable-rate exposure, significant fixed costs, reimbursement reductions, competition and dependence on physician referrals and contracted radiology groups. The business also faces capitation utilization risk, physician recruitment challenges, extensive healthcare regulation, and privacy and cybersecurity risks. The company disclosed ordinary-course litigation and said current matters were not expected to have a material adverse effect. Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting.

Important facts for investors to verify

• Reconcile the fourth-quarter revenue-table label and amounts to the annual statements, and confirm the quarter’s revenue definition.
• Review debt maturity, amortization, covenant headroom, and the refinancing’s realized interest savings, particularly the large first-lien maturity scheduled for 2018.
• Assess receivables growth, collection performance, bad-debt provisions, and the very low year-end cash balance alongside revolver availability.
• Separate recurring operating performance from the debt-extinguishment charge and meaningful-use incentive; note that 2012 earnings included a substantial tax benefit.
• Monitor same-center volumes and reimbursement, capitation profitability, acquisition integration, and compliance risks involving physician arrangements and healthcare regulations.